2009;32:755 61. S7.2.1-15. Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stim- ulation. Circ Arrhythm Electrophysiol. 2013;6:504 12. S7.2.1-16. Hilfiker G, Schoenenberger AW, Erne P, et al. Utility of electro- physiological studies to predict arrhythmic events. World J Cardiol. 2015;7:344 50. S7.2.1-17. Thomas KL, Al-Khatib SM, Lokhnygina Y, et al. Amiodarone use after acute myocardial infarction complicated by heart failure and/ or left ventricular dysfunction may be associated with excess mortal- ity. Am Heart J. 2008;155:87 93. 7.2.2. Primary Prevention of SCD in Patients With NICM S7.2.2-1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225 37. S7.2.2-2. B nsch D, Antz M, Boczor S, et al. Primary prevention of sud- den cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 2002;105:1453 8. S7.2.2-3. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140 50. S7.2.2-4. Desai AS, Fang JC, Maisel WH, et al. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardio- myopathy: a meta-analysis of randomized controlled trials. JAMA. 2004;292:2874 9. S7.2.2-5. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implan- tation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151 8. S7.2.2-6. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic non- sustained ventricular tachycardia AMIOVIRT. J Am Coll Cardiol. 2003;41:1707 12. S7.2.2-7. Anselme F, Moubarak G, Savoure A, et al. Implantable cardioverter- defibrillators in lamin A/C mutation carriers with cardiac conduction disorders. Heart Rhythm. 2013;10:1492 8. 